Breakthrough Nanolaser Promises to Halve Computer Power Consumption

Engineers at the Technical University of Denmark have unveiled a tiny laser that could revolutionize the way computer chips talk to each other. Instead of relying on electricity alone, the new device lets chips exchange information using light, a method that can move data far faster while using dramatically less energy. The laser is so small it fits on a single microchip and works by generating ultra‑precise light pulses that travel through the chip’s circuitry. Early tests suggest that computers equipped with this technology could cut their energy use by up to 50 percent, a gain that would not only lower electricity bills but also reduce the heat generated by data centers and personal devices. The researchers say the nanolaser could be integrated into existing manufacturing processes, meaning future smartphones, laptops, and servers might adopt the technology without a complete redesign. While the work is still in the laboratory stage, the team is optimistic that commercial versions could appear within the next few years, ushering in a new era of faster, greener computing.

Read more

New Hope for Eye Health: How Cutting‑Edge Immune Therapies Are Tackling Retinal Damage

Retinal injury is increasingly recognized as a serious complication of central nervous system (CNS) immune disorders such as multiple sclerosis and lupus. A fresh review brings together the latest laboratory and clinical advances that could change the outlook for patients whose vision is threatened by these hidden attacks. First, researchers have shown that donor‑derived CAR‑T cells—engineered immune cells traditionally used against cancer—can be repurposed to calm autoimmune attacks on the eye, offering symptom relief in early trials. Meanwhile, a team at the University of Science and Technology of China has used messenger‑RNA technology to re‑program the body’s own antigen‑presenting cells, creating a “tolerogenic” shield that stops harmful immune responses in models of rheumatoid arthritis and ulcerative colitis, with promising implications for retinal inflammation. Scientists are also exploring safer biomaterials, such as heparin‑based compounds that bind and neutralize circulating DNA fragments that fuel inflammation, avoiding the toxicity of earlier cationic approaches. On the drug‑target front, the past 25 years have seen a shift from broad cytokine blockers to precise hits on the TNF superfamily, interleukins and downstream kinases, paving the way for personalized treatments. Together, these breakthroughs suggest a future where retinal damage from CNS autoimmunity can be prevented or even reversed, giving patients a clearer, brighter outlook.

Read more